BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

<p>– Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically meaningful and consistent separation observed on measures of mortality, morbidity, function, and quality of life; […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/bridgebio-pharma-reports-second-quarter-2023-financial-results-and-business-update/">BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>